AbbVie (ABBV) Reports Submission of Supplemental New Drug Application to FDA for Venetoclax
Tweet Send to a Friend
AbbVie (NYSE: ABBV) today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
